|
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Since a crosstalk between AGE and angiotensin II (Ang II) has been proposed in the pathogenesis of accelerated atherosclerosis in diabetes, we examined here whether and how telmisartan, a unique Ang II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity, could inhibit AGE-induced CRP expression in a human hepatoma cell line, Hep3B cells.
|
17004092 |
2006 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-γ (PPARγ), liver X receptor-α (LXRα), and PPARγ co-activator-1α (PGC-1α) are nuclear factors that regulate lipid metabolism and inflammation implicated in atherosclerosis.
|
27016616 |
2016 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, PPARγ antagonist GW9662 co-administration mostly blocked these effects, suggesting the important role of PPARγ pathways in mediating 20(S)-Rg3 effects in macrophage polarization and atherosclerosis progression.
|
29867472 |
2018 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that has been suggested to play protective roles in the pathogenesis of diseases that are characterized by chronic inflammation, such as atherosclerosis.
|
18308193 |
2008 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Adipocytokines such as tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), adiponectin, leptin, resistin along with peroxisome proliferator activated receptor-γ (PPAR-γ) are important mediators in glucose homeostasis in association with CD36 and can be used as markers for T2DM and atherosclerosis.
|
21262584 |
2011 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR<sub>γ</sub>) has recently been identified as an attractive target for atherosclerosis intervention.
|
31099308 |
2019 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In the atherosclerosis mice, GQ-177 inhibited atherosclerotic lesion progression, increased plasma HDL and mRNA levels of PPARγ and ATP-binding cassette A1 in atherosclerotic lesions.
|
26706782 |
2016 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, loss of function of PPARγ enhances cardiovascular events and atherosclerosis in the vascular endothelium.
|
31055770 |
2019 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In cardiovascular disease, PPARγ inhibits atherosclerosis but TR4 enhances atherosclerosis through increasing foam cell formation.
|
28527578 |
2017 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The mechanisms by which endothelial PPAR-γ regulates inflammatory responses and protects against atherosclerosis remain unclear.
|
26566726 |
2016 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Together, these results indicate that the stimulation of SR-B1 expression in the liver is mediated in part by activation of the PPAR-gamma and RXR, and raise the possibility that this stimulation using thiazolidinediones conditions provides a protective mechanism for accelerated atherosclerosis in diabetes mellitus.
|
19156545 |
2009 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator activated receptor gamma (PPARgamma) modulates atherosclerosis by its anti-inflammatory and anti-protease activity.
|
16311343 |
2005 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Aortic wall shows histopathological evidence of atherosclerosis in obesity group which is more evident in atherosclerotic group, and milder changes upon receiving PPARγ agonist.
|
30612469 |
2019 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Although activation of PPARgamma appears to have beneficial effects on atherosclerosis and heart failure, it is still largely uncertain whether PPARgamma ligands prevent the development of cardiovascular diseases.
|
12861348 |
2003 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor involved in such cellular processes as adipogenesis, inflammation, atherosclerosis, cell cycle control, apoptosis, and carcinogenesis.
|
12364466 |
2002 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Metabolic reprogramming in atherosclerosis: Opposed interplay between the canonical WNT/β-catenin pathway and PPARγ.
|
31153873 |
2019 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
For the first time we demonstrate that CRP modulates PPAR-gamma and its effector genes and reinforces the mechanistic link of CRP as a possible mediator in atherosclerosis and also advocate atorvastatin as a therapeutic modality.
|
20682172 |
2010 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results establish a role for PPARgamma in the regulation of EC gene expression, with important implications for the clinical links between obesity and atherosclerosis.
|
10073956 |
1999 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We explored whether TNF-α could promote atherosclerosis by increasing the transcytosis of lipoproteins (e.g., LDL) across endothelial cells and how NF-κB and PPAR-γ were involved in this process.
|
24594319 |
2014 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Brachiocephalic arteries from TRAIL(-/-)ApoE(-/-) and ApoE(-/-) mice fed a high fat diet for 12 w demonstrated increased chondrocyte-like cells in atherosclerotic plaque, as well as increased aortic collagen II mRNA expression in TRAIL(-/-)ApoE(-/-) mice, with significant increases in calcification observed at 20 w. TRAIL(-/-)ApoE(-/-) aortas also had significantly elevated RANKL, BMP-2, IL-1β, and PPAR-γ expression at 12 w. Our data provides the first evidence that TRAIL deficiency results in accelerated cartilaginous metaplasia and calcification in atherosclerosis, and that TRAIL plays an important role in the regulation of RANKL and inflammatory markers mediating bone turn over in the vasculature.
|
24040204 |
2013 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
|
20508203 |
2010 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In early lesions, PPARG was identified as a specific master regulator of the PCL-responsive atherosclerosis TF-regulatory network, whereas in mature and advanced lesions, the specific master regulators were MLL5 and SRSF10/XRN2, respectively.
|
24586211 |
2014 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
|
16259527 |
2005 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Macrophage foam cell formation by oxidized low-density lipoprotein (oxLDL) is a key step in the progression of atherosclerosis, which is involved in cholesterol influx and efflux in macrophages mediated by related proteins such as peroxisome proliferator-activated receptor γ (PPARγ), CD36, PPARα, liver-X receptor α (LXRα), and ATP-binding cassette transporter A1 (ABCA1).
|
25010893 |
2014 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis.
|
21700710 |
2011 |